Radical Resection in an Era of Immune Therapy for Primary Esophageal Melanoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35218701.
- Also identified by DOI 10.1016/j.athoracsur.2022.01.063.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Primary malignant melanoma of the esophagus (PMME) is a rare and aggressive esophageal malignant neoplasm demonstrating poor overall survival. Immunotherapy (IO) is now established as a therapy for aggressive or metastatic cutaneous malignant melanoma. This case series discusses IO for PMME in both the perioperative and salvage setting for curative intent. IO is changing the treatment approaches for PMME and may lead to long-term salvage and survival.
Medical subject headings
- Esophageal Neoplasms
- Melanoma
- Neoplasms, Second Primary
- Skin Neoplasms